{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T04:49:01Z","timestamp":1770266941229,"version":"3.49.0"},"reference-count":28,"publisher":"Academy of Managed Care Pharmacy","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.18553\/jmcp.2026.32.2.135","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:32:00Z","timestamp":1770219120000},"page":"135-142","source":"Crossref","is-referenced-by-count":0,"title":["Real-world adherence to and persistence with emicizumab in people with hemophilia A using a national claims database"],"prefix":"10.18553","volume":"32","author":[{"given":"Janet S.","family":"Lee","sequence":"first","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Schuldt","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyu","family":"Xia","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Lee","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana M. L.","family":"Biondo","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy D.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Indiana Hemophilia & Thrombosis Center, Indianapolis"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7818","reference":[{"key":"r1","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep15010014"},{"key":"r2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"r3","unstructured":"National Hemophilia Foundation. MASAC recommendation concerning prophylaxis for hemophilia A and B with and without inhibitors. Published 2022. Accessed October 27, 2025. https:\/\/www.bleeding.org\/sites\/default\/files\/document\/files\/267_Prophylaxis.pdf"},{"issue":"2","key":"r4","first-page":"152","volume":"18","author":"Zanon E","year":"2020","journal-title":"Blood Transfus"},{"key":"r5","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12533"},{"key":"r6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187387"},{"key":"r7","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12360"},{"key":"r8","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S139851"},{"key":"r9","unstructured":"Eloctate (antihemophilic factor [recombinant] Fc fusion protein). Prescribing information. Sanofi; 2023. Accessed February 18, 2025. https:\/\/products.sanofi.us\/eloctate\/eloctate.pdf"},{"key":"r10","unstructured":"Altuviiio (antihemophilic factor [recombinant], Fc-VWF-XTEN fusion protein-ehtl). Prescribing information. Sanofi; 2023. Accessed February 18, 2025. https:\/\/products.sanofi.us\/altuviiio\/altuviiio.pdf"},{"key":"r11","unstructured":"Advate (antihemophilic factor [recombinant]). Prescribing information. Takeda Pharmaceuticals U.S.A., Inc.; 2023. Accessed February 18, 2025. https:\/\/www.shirecontent.com\/PI\/PDFs\/ADVATE_USA_ENG.pdf"},{"key":"r12","unstructured":"Adynovate (antihemophilic factor, recombinant, PEGylated). Prescribing information. Takeda Pharmaceuticals U.S.A., Inc.; 2023. Accessed February 18, 2025. https:\/\/www.shirecontent.com\/PI\/PDFs\/ADYNOVATE_USA_ENG.pdf"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12660"},{"key":"r14","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12951"},{"key":"r15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169880"},{"key":"r16","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14324"},{"key":"r17","unstructured":"Hemlibra (emicizumab). Prescribing information. Genentech, Inc.; 2024. Accessed February 18, 2025. https:\/\/www.gene.com\/download\/pdf\/hemlibra_prescribing.pdf"},{"key":"r18","unstructured":"Hussain A, Thompson A, Divney AA, Avalos-Reyes E, Watkins N, Patel N. Retrospective review of hemophilia patients before and after treatment with emicizumab. National Bleeding Disorders Foundation. Published 2020. Accessed February 18, 2025. https:\/\/www.bleeding.org\/research\/research-projects\/retrospective-review-of-hemophilia-patients-before-and-after-treatment-with-emicizumab"},{"key":"r19","unstructured":"Watkins N, Thompson A, Hussain A, Patel N, Avalos-Reyes E, Divney A. Retrospective review of hemophilia patients before and after treatment with emicizumab. Poster presented at: National Hemophilia Foundation Bleeding Disorders Conference; August 1-8, 2020."},{"key":"r20","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14851"},{"key":"r21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169861"},{"key":"r22","first-page":"70","volume":"28","author":"Khairnar R","year":"2022","journal-title":"Haemophilia"},{"key":"r23","unstructured":"IQVIA. IQVIA PharMetrics\n                      \u00ae\n                      Plus fact sheet. Published April 8, 2022. Accessed December 11, 2024. https:\/\/www.iqvia.com\/locations\/united-states\/library\/fact-sheets\/iqvia-pharmetrics-plus"},{"key":"r24","unstructured":"National Hemophilia Foundation. MASAC recommendations regarding doses of clotting factor concentrate in the home. Published 2016. Accessed December 11, 2024. https:\/\/www.bleeding.org\/sites\/default\/files\/document\/files\/242.pdf"},{"key":"r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102364"},{"key":"r26","unstructured":"Centers for Disease Control and Prevention. Data and statistics on hemophilia. Published May 15, 2024. Accessed February 18, 2025. https:\/\/www.cdc.gov\/hemophilia\/data-research\/index.html"},{"key":"r27","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14535"},{"key":"r28","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14232"}],"container-title":["Journal of Managed Care & Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:32:20Z","timestamp":1770219140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2026.32.2.135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.18553\/jmcp.2026.32.2.135"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2026.32.2.135","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}